Emergent BioSolutions | EBS - Stammkapital





Stammkapital Veränderung Datum
Acadia Pharmaceuticals USD 172.31M 174K 2026-09
Akebia Therapeutics USD 265.42M 199K 2025-12
ALKERMES USD 168.03M 489K 2026-09
Alnylam Pharmaceuticals USD 133.88M 141K 2026-09
Amarin USD 20.81M 13K 2025-12
ANI Pharmaceuticals USD 22.49M 760K 2025-12
BioMarin Pharmaceutical USD 193.68M 141K 2026-09
Coherus Biosciences USD 121.16M 4.92M 2025-12
Emergent BioSolutions USD 100K 0 2023-06
Exelixis USD 244.68M 4.21M 2026-09
Glaxosmithkline GBP 2.02B 2.03B 2026-09
Heron Therapeutics USD 188.31M 4.99M 2025-12
Ionis Pharmaceuticals USD 166.41M 773K 2026-09
Ironwood Pharmaceuticals USD 160K 0 2024-12
Lexicon Pharmaceuticals USD 363.47M 67K 2025-12
Lonza CHF 68.64M 0 2025-12
Merck USD 2.47B 1.05M 2026-06
Moderna USD 391M 2M 2025-09
Myriad Genetics USD 93.5M 400K 2025-12
Nektar Therapeutics USD 29.47M 9.09M 2026-03
Neurocrine Biosciences USD 101.3M 750K 2026-09
Pacira USD 39.9M 75K 2026-09
Pfizer USD 5.7B 1000K 2026-09
PTC Therapeutics USD 83.33M 445K 2026-06
Sanofi EUR 1.2B 0 2026-09
Sarepta Therapeutics USD 107.23M 1.61M 2026-09
United Therapeutics USD 42.38M 295K 2026-09
Vanda Pharmaceuticals USD 58K 0 2024-12